• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Tekturna Side Effect Lawsuits
 

Tekturna Side Effect Lawsuits

on

  • 1,446 views

Do you have Tekturna safety concerns? Ask your doctor and your lawyer. While high blood pressure is serious; the antidote should not be more threatening.

Do you have Tekturna safety concerns? Ask your doctor and your lawyer. While high blood pressure is serious; the antidote should not be more threatening.

Statistics

Views

Total Views
1,446
Views on SlideShare
1,446
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

CC Attribution-NonCommercial LicenseCC Attribution-NonCommercial License

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Tekturna Side Effect Lawsuits Tekturna Side Effect Lawsuits Document Transcript

    • Tekturna Safety Concerns According to the National Heart Lung & Blood Institute, one in three adults in the United States have high blood pressure. That sounds like an epidemic health problem. Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps blood. If this pressure rises and stays high over time, it can damage the body. High blood pressure increases the risk of fatal and nonfatal heart problems, primarily strokes and heart attacks. Controlling blood pressure includes controlling cholesterol, managing diabetes, stopping smoking, starting an exercise program, maintaining a healthy weight, limiting salt and alcohol, coping with stress through yoga and meditation, and taking the proper heart related medications. Medications to lower high blood pressure like Tekturna should be trustworthy vs. worrisome and not plague us with Tekturna safety concerns. Like other medical disorders and diseases, occasionally one medication is not enough to solve the problem or keep it in check. Some medications work more effectively when piggy-backed or combined. For people with high risk medical conditions like Type 2 diabetes or high cholesterol, reducing blood pressure is a greater benefit than for people who are not already at high medical risk. High risk people benefit from more aggressive treatment like being prescribed more than one medication to lower high blood pressure. For adults who have diabetes or chronic kidney disease, blood pressure should be below 130/80. For more information contact: Risk factors for high blood pressure are age (60+), ethnicity – African Anapol Schwartz P .C. Americans have higher blood pressure than Caucasians and Hispanics, (866) 735-2792 genetic factors, lack of exercise, obesity, and poor lifestyle choices. Thomas R. Anapol, Esquire or Do you have Tekturna safety concerns? Ask your doctor and your Michael H. Monheit, Esquire lawyer. While high blood pressure is serious; the antidote should not be ©2012 All Rights Reserved. more threatening.MEDICAL DISCLAIMER: This PDF is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services or otherwise engage in the practice ofmedicine, to you or to any other individual. Please use this information to help in your conversation with your physician. This is general information and always seek the advice of yourphysician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard or delay seeking professional medical advice or treatmentbecause of content found in the PDF, website, or newsletter.ATTORNEY DISCLAIMER: This PDF is dedicated to providing general public information regarding legal rights. None of the information on this PDF is intended to be formal legaladvice, nor the formation of a lawyer or attorney client relationship. Please contact a Lawyer for information regarding your particular case. This PDF is not intended to solicit clientsoutside the states of Pennsylvania, New Jersey, Ohio, West Virginia and Arizona.
    • Tekturna Problems Tekturna is a drug manufactured by Novartis prescribed to lower high blood pressure, more formerly known as hypertension. The drug was approved in 2007 in the United States and in Europe under the brand Rasilez. With different names, the drug was intended as a monotherapy (single drug) or to be used with other medications treating hypertension. Its generic name is aliskiren. On December 20, 2011, Novartis announced their decision to terminate a clinical trial on the recommendation of the independent Data Monitoring Committee or DMC which was overseeing the ALTITUDE study. The Data Monitoring Committee found that patients were unlikely to benefit when Rasilez/Tekturna was added to their standard blood pressure medication regimen. Worse – there was an increased risk after 18-24 months of non-fatal stroke, kidney problems, hyperkalemia (high levels of potassium in the blood), and hypotension (extreme low blood pressure) for people with Type 2 diabetes, an already high risk population. Tekturna Side Effects Are Serious. FDA From April 2007 to September 2011 the FDA received 7489 reports of reactions related to the use of Tekturna. These reports introduced 1045 types of reactions including the most commonly reported dizziness, blood pressure increased, diarrhoea, blood pressure inadequately controlled and headache.Copyright © 2012 All rights reserved. Anapol Schwartz PRead more information online at www.anapolschwartz.com. .C. Tekturna ||
    • Timeline for Novartis Tekturna In December 2011 the drug maker Novartis halted an important trial of Tekturna in patients with diabetes because some participants experienced more non-fatal strokes and Tekturna kidney disease. The drug was first approved in 2007 to lower blood pressure. Tekturna experienced sales of $449 million in the first nine months of the year. When a clinical trial is halted because of serious adverse side effects like Tekturna strokes and Tekturna kidney disease, the pharmaceutical company and its investors pause. Analysts estimated that Tekturna sales would be around $1.4 billion by the year 2016 but now with the serious Tekturna strokes and kidney disease during the trial, large numbers (dollars) will diminish. None of this is good news for Novartis. In 2010 Novartis had to pay $422 million to settle a U.S. Department of Justice and whistleblower lawsuit. Many of the allegations targeted off-label promotion of another drug, an epilepsy drug called Trileptal. However, heart related drugs were also targeted and Tekturna was one of them. Off label promotion means when a prescription medicine is used to treat a disease or condition for which the drug has not been approved by the FDA. While the FDA regulates how a medication can be advertised or promoted by the manufacturer, these regulations do not restrict a doctor’s ability to prescribe the medication for different conditions, in different doses, or for different lengths of time. Novartis promoted the use of Tekturna for diabetes patients when in fact clinical trials did not provide any benefits. As a matter of fact, diabetes patients may be seriously harmed by using Tekturna. Novartis haltsclinical trials in December 2011. A clinical trial called ALTITUDE which was comprised of 8,606 patients in 36 countries has influenced taking Tekturna off the market. It appears that Tekturna caused a greater risk for non-fatal stroke and kidney complications.Copyright © 2012 All rights reserved. Anapol Schwartz PRead more information online at www.anapolschwartz.com. .C. Tekturna ||
    • The Novartis Tekturna study abruptly ended in December 2011 because Novartis found no added benefit and an increase in adverse side effects. Some of the Tekturna side effects included strokes, kidney problems, high potassium levels and low blood pressure.These are very dangerous side effects for people with diabetes, an already high risk population. Tekturna has not yet been recalled by the FDA. However, the drug regulation agency in Europe is reviewing the drug’s safety and patients included in the study are being urged to speak to their doctors about whether they should continue on Tekturna treatment. If you are taking Tekturna you should likewise speak to your doctor about the Altitude study and about whether the potential benefits of Tekturna outweigh the possible risks for you. Do You Have a Tekturna Stroke Lawsuit? Have you or a loved one been seriously harmed by Tekturna problems? Contact us for a free consultation with one of our award-winning lawyers toll free at (866) 735-2792.Copyright © 2012 All rights reserved. Anapol Schwartz PRead more information online at www.anapolschwartz.com. .C. Tekturna ||